<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM IMMULOGIC PHARMACEUTICAL CORPORATIONS FINANCIAL STATEMENTS FILED IN Q1 1999 QUARTERLY REPORT ON FORM 10-Q CONDENSED CONSOLIDATED BALANCE SHEET AND INCOME STATEMENT AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FORM 10-Q DATED JUNE 30, 1999. </LEGEND> <MULTIPLIER> 1,000 <CURRENCY> U.S. DOLLARS <PERIOD-TYPE> 3-MOS <FISCAL-YEAR-END> DEC-31-1999 <PERIOD-START> APR-01-1999 <PERIOD-END> JUN-30-1999 <EXCHANGE-RATE> 1 <CASH> 24,878 <SECURITIES> 25,539 <RECEIVABLES> 0 <ALLOWANCES> 0 <INVENTORY> 0 <CURRENT-ASSETS> 33,187 <PP&E> 0 <DEPRECIATION> 0 <TOTAL-ASSETS> 52,665 <CURRENT-LIABILITIES> 1,826 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 204 <OTHER-SE> 50,635 <TOTAL-LIABILITY-AND-EQUITY> 52,665 <SALES> 0 <TOTAL-REVENUES> 348 <CGS> 0 <TOTAL-COSTS> 348 <OTHER-EXPENSES> 1,598 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 0 <INCOME-PRETAX> (1,072) <INCOME-TAX> 0 <INCOME-CONTINUING> (1,072) <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> (1,072) <EPS-BASIC> (0.05) <EPS-DILUTED> (0.05) <FN> <F1>MARKETABLE SECURITIES INCLUDES $17,411 IN LONG-TERM INVESTMENTS. </FN>